Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Bekeken
• 07/18/23
0
0
insluiten
administrator
abonnees
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties